<DOC>
	<DOC>NCT03095456</DOC>
	<brief_summary>This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHalerÂ® on lung function in subjects with COPD and a Low Peak Inspiratory Flow Rate.</brief_summary>
	<brief_title>Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Subject is a male or female subject 40 years of age or older with a diagnosis of COPD. Subject has a current or past cigarette smoking history (or equivalent for cigar or pipe smoking history) of at least 10 packyears. Subject is willing and able to provide signed and dated written informed consent to participate prior to initiation of any study related procedures. Subject has a concurrent disease or condition that, in the opinion of the investigator, would interfere with continued study participation or confound the evaluation of safety and tolerability of the study drug. Subject has a history of reactions or hypersensitivity to inhaled or nebulized anticholinergics. Subject suffers from any medical condition that would preclude the use of inhaled anticholinergics, including narrowangle glaucoma, symptomatic benign prostatic hyperplasia, bladder neck obstruction, or urinary retention.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate</keyword>
</DOC>